LLY Analyst Ratings

UBS resumed Eli Lilly at Buy ($1250) in January, the highest target on the Street. Daiwa upgraded to Buy ($1230) in December and Goldman raised to $1145. Consensus is Buy at $401 average target — GLP-1 dominance with Mounjaro and Zepbound keeping analysts firmly bullish.

ANALYST RATINGS
Buy$1060
LLY
Buy$1250
Resumed
2026-01-07
Buy$1230
Upgrade
2025-12-16
Buy$1145
Reiterated
2025-12-15
Buy$1268
Reiterated
2025-12-15
Sector Outperform$1165
Initiated
2025-11-13
Resumed
2026-01-07
UBS
RatingBuy
From—
Target$1250
From—
Upgrade
2025-12-16
Daiwa Securities
RatingBuy
FromNeutral
Target$1230
From—
Reiterated
2025-12-15
Goldman
RatingBuy
From—
Target$1145
From$951
Reiterated
2025-12-15
BofA Securities
RatingBuy
From—
Target$1268
From$1286
Initiated
2025-11-13
Scotiabank
RatingSector Outperform
From—
Target$1165
From—
Upgrade
2025-11-10
Leerink Partners
RatingOutperform
FromMarket Perform
Target$1104
From—
Reiterated
2025-10-20
BMO Capital Markets
RatingOutperform
From—
Target$930
From$840
Downgrade
2025-09-17
Berenberg
RatingHold
FromBuy
Target$830
From—
Upgrade
2025-08-27
HSBC Securities
RatingHold
FromReduce
Target$700
From—
Downgrade
2025-08-18
Daiwa Securities
RatingNeutral
FromOutperform
Target$700
From—
Downgrade
2025-08-07
Leerink Partners
RatingMarket Perform
FromOutperform
Target$715
From—
Downgrade
2025-04-28
HSBC Securities
RatingReduce
FromBuy
Target$700
From$1150
Initiated
2025-04-22
Cantor Fitzgerald
RatingOverweight
From—
Target$975
From—
Resumed
2024-12-10
BofA Securities
RatingBuy
From—
Target$997
From—
Initiated
2024-11-15
Wolfe Research
RatingOutperform
From—
Target$1000
From—
Initiated
2024-10-17
Bernstein
RatingOutperform
From—
Target$1100
From—
Resumed
2024-09-13
Citigroup
RatingBuy
From—
Target$1060
From—
Upgrade
2024-08-12
Deutsche Bank
RatingBuy
FromHold
Target$1025
From—